Publications scientifiques en hépatologie
Treatment with growth hormone releasing hormone analog reduces VEGF-A, TGFfβ-1, and CSF-1: Mechanisms of tesamorelin effect in nonalcoholic fatty liver disease [abstract].
2020
Hepatology.
Stanley TL, Fourman LT, Billingsley JM, et al.
72(suppl 1):142. Proceedings of The Liver Meeting (AASLD) 2020.
Treatment with growth hormone releasing hormone analog reduces VEGF-A, TGFfβ-1, and CSF-1: Mechanisms of tesamorelin effect in nonalcoholic fatty liver disease.
2020
Fourman LT.
Oral presentation #142 at: Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting); November 13-16, 2020; virtual.
Clinical predictors of liver fibrosis presence and progression in HIV-associated NAFLD [abstract].
2020
Top Antivir Med.
Fourman LT, Stanley TL, Feldpausch M, et al.
28(1):128. Proceedings of the Conference on Retroviruses and Opportunistic Infections, 2020.
Clinical predictors of liver fibrosis presence and progression in HIV-associated NAFLD.
2020
Fourman LT, Stanley TL, Feldpausch M, et al.
Oral presentation #128 at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts, USA. Session O-10.
Clinical predictors of liver fibrosis presence and progression in HIV-associated NAFLD.
2020
Clin Infect Dis.
Fourman LT, Stanley TL, Zheng I, et al.
ciaa382.